RECENT NEWSPress Release 2008-24-07 - GLYCOTOPE GmbH acquires GMP production site of ORPEGEN in Heidelberg Press Release 2007-29-10 - Founders in Berlin-Buch close Financing Round for Glycotope Press Release 2006-08-01 - Glycotope is ready to enter into negotiations with international investors Press Release 2005-10-05 - Glycotope ISO 9001-2000 certified Press Release 2004-07-05 - Glycotope presents Novel GlycoExpress™ Technology Press Release 2004-27-04 - Glycotope receive 1.6 Mio. Euro grantRECENT PUBLICATIONSCao,Y., Merling,A., Karsten,U., Goletz,S., Punzel,M., Kraft,R., Butschak,G., Schwartz-Albiez,R.: Expression of CD175 (Tn), CD175s (sialosyl-Tn), and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. In: Int.J.Cancer 2008: Vol 123.Christensen,P.A., Danielczyk,A., Ravn,P., Stahn,R., Karsten,U., Goletz,S.: A monoclonal antibody to Lewis Y/Lewis b revealing mimicry of the histone H1 to carbohydrate structures. In: Scand.J.Immunol. 2007: Vol 65. Ravn,P., Stahn,R., Danielczyk,A., Faulstich,D., Karsten,U., Goletz,S.: The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs. In: Cancer Immunol.Immunother. 2007: Vol 56. Butschak,G., Karsten,U., Schelhaas,U., Ott,H., Emmendörffer,A., Niemeyer,B., Helmholz,H., Goletz,S.: Detection, isolation and partial characterization of an immunostimulating glycoprotein from Rhodococcus fascians. In: Internat.Immunopharmacol. 2006: Vol 6. Jeschke,U., Kuhn,C., Mylonas,I., Schulze,S., Friese,K., Mayr,D., Speer,R., Briese,V., Richter,D.-U., Haase,M., Karsten,U.: Development and characterization of monoclonal antibodies for the immunohistochemical detection of glycodelin A in decidual, endometrial and gynaecological tumour tissues. In: Histopathology 2006: Vol 48. Danielczyk,A., Stahn,R., Faulstich,D., Löffler,A., Märten,A., Karsten,U., Goletz,S.: PankoMab: a potent new generation anti-tumour MUC1 antibody. In: Cancer Immunol.Immunother. 2006: Vol 55. Karsten U, von Mensdorff-Pouilly S, Goletz S. What Makes MUC1 a Tumor Antigen? In: Tumor Biology 2005: Vol. 26. Ravn P, Danielczyk A, Jensen KB, Kristensen P, Christensen PA, Larsen M, Karsten U, Goletz S. Multivalent scFv Display of Phagemid Repertoires for the Selection of Carbohydrate-specific Antibodies and its Application to the Thomsen-Friedenreich Antigen. In: J. Mol. Biol. 2004: Vol 343. Christensen PA, Danielczyk A, Stahn R, Goletz S. Simple separation of DNA in antibody purification. In: Protein Expression and Purification 2004: Vol 37. Goletz S, Cao Y, Danielczyk A, Ravn P, Schoeber U, Karsten U. Thomsen-Friedenreich Antigen: The "hidden" tumor antigen. In: Advances in experimental medicine and biology: Glycobiology and medicine 2003: Vol 535. RECENT ARTICLESBaumeister H, Goletz S. GlycoExpress: A novel expression system for the optimal glycosylation of biotherapeutics. In: Speciality Chemicals Magazine 2005: Vol 25.Baumeister H, Schoeber U, Schlangstedt M, Stahn R, Goletz S. A novel human expression system for generating glycoprotein with higher activity, fully human glycosylation, and optimised sialylation. In: BioProcessing Journal 2005: Vol 4. Baumeister H, Goletz S. Voll funktionsfähige humane dendritische Zelllinie. In: Laborwelt 2005: Vol 6. Goletz S, Baumeister H. Opportunities with NEMOD & GLYCOTOPE. In: R&D FOCUS drugnews 2004: Vol 13. Baumeister H. GlycoEngineering - a Technology for Production of Glycoproteins. In: BioTOPics 2004: Vol 24. Baumeister H, Goletz S. A novel technology for the production of highly active therapeutic proteins. In: DrugPlus international 2004: Vol 03. For any inquiries regarding news or publications, please contact: |
|
GLYCOTOPE GmbH Robert-Rössle-Str. 10 13125 Berlin Germany Mr. Marcel Kühnert Business Manager |
| Telephone: Fax: E-mail: |
+49-30-9489-2603 +49-30-9489-2609 marcel.kuehnert@glycotope.com |